Key Insights

Highlights

Success Rate

66% trial completion

Published Results

43 trials with published results (20%)

Research Maturity

79 completed trials (37% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

18.9%

40 terminated out of 212 trials

Success Rate

66.4%

-20.2% vs benchmark

Late-Stage Pipeline

5%

11 trials in Phase 3/4

Results Transparency

54%

43 of 79 completed with results

Key Signals

43 with results66% success40 terminated

Data Visualizations

Phase Distribution

177Total
Not Applicable (16)
Early P 1 (5)
P 1 (86)
P 2 (59)
P 3 (7)
P 4 (4)

Trial Status

Completed79
Terminated40
Recruiting38
Unknown19
Active Not Recruiting16
Withdrawn9

Trial Success Rate

66.4%

Benchmark: 86.5%

Based on 79 completed trials

Clinical Trials (212)

Showing 20 of 20 trials
NCT03830229RecruitingPrimary

Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1

NCT05278975Phase 1Completed

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

NCT07277413Phase 1Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT02414269Phase 1Active Not Recruiting

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT06057935Phase 2Recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

NCT03075527Phase 2TerminatedPrimary

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

NCT07705334Phase 1Recruiting

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

NCT07705074Phase 1Not Yet Recruiting

FAPI PET Imaging - An Exploratory Study

NCT05451849Phase 1TerminatedPrimary

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05873686Phase 1Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

NCT01950572Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT05579366Phase 1Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT06466187Phase 1Terminated

A Study of SGN-MesoC2 in Advanced Solid Tumors

NCT06996249Recruiting

Prospective Data Collection Initiative on Thoracic Malignancies

NCT06710756Phase 1Recruiting

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT05571839Phase 1Terminated

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT04431024Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT04857372Phase 1Active Not RecruitingPrimary

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT06885697Phase 1RecruitingPrimary

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Scroll to load more

Research Network

Activity Timeline